{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-26-000003","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.043428+00:00","generated_at":"2026-05-16T03:34:13.171994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"iBio reports Q2 FY2026 operating loss; secures $26M PIPE financing led by Frazier Life Sciences","bullets":["No revenue for Q2 ended Dec 31, 2025, vs $0.2M a year ago; R&D expense $4.3M, G&A $5.2M (includes impairment of IBIO-101 intangible).","Cash and investments of $52.7M at Dec 31, 2025; net proceeds of ~$24.4M from January PIPE extend runway into Q3 FY2028.","IBIO-600 (myostatin antibody) on track for Phase 1a clinical trial in H1 2026; IBIO-610 (activin E) aims for first human trials early 2027.","NHP data for IBIO-610 shows predicted human half-life up to 100 days, supporting twice-yearly dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-26-000003","json":"https://secwatch.observer/filing/0001420720-26-000003.json","markdown":"https://secwatch.observer/filing/0001420720-26-000003.md","text":"https://secwatch.observer/filing/0001420720-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000003/0001420720-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000003/ibio-20260210x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:34:13.171994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}